Cabazitaxel (Jevtana), a chemotherapy drug used with prednisone for prostate cancer. ... It is the first treatment for advanced, hormone-refractory prostate cancer that has worsened during or after treatment with docetaxel.
two more years of follow-up results in the European Randomized Study of Screening for Prostate Cancer. ... We are left with an unsatisfactory situation, in which many practitioners will think there are insufficient data to recommend abandoning PSA
Estimates suggest that needle biopsy would diagnose 32% of them with prostate cancer. ... Many contemporary men receiving treatment for localized prostate cancer are unlikely to benefit from the intervention,” the authors wrote.
An expanded approval of abiraterone acetate (Zytiga) to treat metastatic castration-resistant prostate cancer prior to chemotherapy. ... The drug was initially approved in November 2011 for use in patients whose prostate cancer progressed after treatment
found. Decision aids improved participants' informed decision making about prostate cancer screening but did not change the actual screening rates, a study found. ... one month and 13 months for prostate cancer knowledge, decisional conflict, decisional
The primary outcome of this study was prostate cancer mortality at a median of 10 years of follow-up. ... An accompanying editorial for both studies stated that active monitoring, as compared with treatment of early prostate cancer, leads to increased
Sipuleucel-T (Provenge), autologous cellular immunotherapy approved to treat asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment. ... cancer. Most of the studies
Prostate cancer mortality varied according to disease risk but not by number of comorbid conditions. ... 3.3), respectively, in the subhazard of prostate cancer mortality compared with those treated aggressively.
Radical prostatectomy was associated with fewer deaths from prostate cancer compared to watchful waiting, a Scandinavian study found. ... Two large, randomized, controlled trials are under way to determine whether treatment will reduce mortality in men
Cheatham. Another etiology of rectal bleeding is radiation proctitis, which typically develops one to two years after radiation exposure in those treated for cervical cancer or prostate cancer, he noted. ... Cheatham. Finally, he said, cancer is an